Results

1–10 of 41 results for age-related macular degeneration (AMD)

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Durga Borkar, MD
Annual Meeting Talks
2022
Association of Metformin and Other Antidiabetic Medication Use with Risk of Age-Related Macular Degeneration
Dimitra Skondra, MD,PhD
Annual Meeting Talks
2022
Unsupervised Deep Learning for Grading Age-Related Macular Degeneration Using Retinal Fundus Images
Neesurg S Mehta, MD
On Demand Cases, Courses, and Papers
2021
Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021